Bavarian Nordic’s smallpox vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada.
Bavarian Nordic A/S announced today the signing of a number of supply contracts with undisclosed countries for the company’s smallpox vaccine with the aim to ensure sufficient supply to meet the requirements for vaccinating individuals at risk for monkeypox in the short to medium term.
Read more here
